SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
CAAA601A22301
Phase 3 small_molecule active
Quick answer
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion for Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs is a Phase 3 program (small_molecule) at Advanced Accelerator Applications with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Advanced Accelerator Applications
- Indication
- Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active